Growth & profitability
- Revenue has grown 2511.6% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
RNXT Financials RenovoRx, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$11M | 70.9% | -1114.0% | -$11M | — | $7M |
| 2024 | $43000 | -$9M | 100.0% | -25511.6% | -$9M | — | $7M |
| 2023 | — | -$10M | — | — | — | — | $1M |
| 2022 | — | -$10M | — | — | — | — | $4M |
| 2021 | — | -$6M | — | — | — | — | $15M |
| 2020 | — | -$4M | — | — | — | — | $2M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $563000 | -$4M | 85.1% | -616.2% | -$4M | — | $12M |
| Dec '25 | $238000 | -$3M | 88.2% | -1479.8% | -$3M | — | $7M |
| Sep '25 | $266000 | -$3M | 80.1% | -1203.0% | -$2M | — | $10M |
| Jun '25 | $422000 | -$3M | 64.0% | -634.6% | -$2M | — | $12M |
| Mar '25 | $197000 | -$2M | 52.3% | -1578.7% | -$3M | — | $15M |
| Dec '24 | — | -$3M | — | — | — | — | $7M |
| Sep '24 | — | -$2M | — | — | — | — | $10M |
| Jun '24 | — | -$2M | — | — | — | — | $12M |
| Mar '24 | — | -$1M | — | — | — | — | $4M |
| Dec '23 | — | -$3M | — | — | — | — | $1M |
| Sep '23 | — | -$1M | — | — | — | — | $3M |
| Jun '23 | — | -$2M | — | — | — | — | $6M |
| Mar '23 | — | -$3M | — | — | — | — | $4M |
| Dec '22 | — | -$2M | — | — | — | — | $4M |
| Sep '22 | — | -$2M | — | — | — | — | $3M |
| Jun '22 | — | -$3M | — | — | — | — | $3M |
| Mar '22 | — | -$3M | — | — | — | — | $13M |
| Dec '21 | — | -$2M | — | — | — | — | $15M |
| Sep '21 | — | -$2M | — | — | — | — | $18M |
| Jun '21 | — | -$1M | — | — | — | — | — |
Valuation over time
How the market has priced RNXT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 1363.5× (Dec '24) to 37.5× (Jun '26).
P/S
Frequently asked questions
Is RNXT growing its revenue and profit?
Over the past 5 years, RenovoRx, Inc.'s revenue has grown 2511.6% per year. These are computed facts, not advice.
How much debt does RNXT have?
As of FY2025, RenovoRx, Inc. reported — of total debt against $7M of cash.
What is RNXT's profit margin?
In FY2025, gross margin was 70.9%, operating margin -1114.0%, and net margin -994.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.